Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in L'hospitalet De Llobregat – page 32

988 clinical trials in L'hospitalet De Llobregat, Spain across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
L'hospitalet De Llobregat at a glance
988
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

988 trials in L'hospitalet De Llobregat

Open in trial search

Atrial fibrillation

Not yet recruiting

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:REGN7508
  • Sponsor:Regeneron Pharmaceuticals Inc.

Ovarian cancer

Not yet recruiting

Phase 2 Study of Trastuzumab Deruxtecan plus Bevacizumab versus Standard Chemotherapy in Patients with Recurrent Ovarian Cancer after PARP Inhibitor Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico

Choroid melanoma

Not yet recruiting

Long‑Term Follow‑Up Study of Belzupacap Sarotalocan in Patients with Early Choroidal Melanoma

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Belzupacap Sarotalocan
  • Sponsor:Aura Biosciences Inc.

End stage renal disease+1

Not yet recruiting

Safety and efficacy of locally administered APAC, heparin sodium and sodium chloride to promote arteriovenous fistula maturation in patients with end‑stage kidney disease

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Heparin Sodium
  • Sponsor:Aplagon Oy

Phase III Randomized Open‑Label Trial of BNT324 vs Docetaxel Plus Prednisone in Patients with Metastatic Castration‑Resistant Prostate Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:BioNTech SE

Evaluating the efficacy and safety of CRD-4730 in patients with heart failure with reduced ejection fraction

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:CRD-4730
  • Sponsor:Cardurion Pharmaceuticals Inc.

Spinal muscular atrophy

Not yet recruiting

Study of BIIB115 in patients aged 15‑60 years with spinal muscular atrophy who are treatment‑naïve or previously treated with risdiplam

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:BIIB115
  • Sponsor:Biogen Idec Research Limited

Disease risk factor+1

Not yet recruiting

Colchicine for Reducing Dependency and Vascular Events in Patients After Acute Intracerebral Hemorrhage

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Hamilton Health Sciences Corporation

Non-small cell lung cancer

Not yet recruiting

Phase 3 Study of Taletrectinib as Adjuvant Therapy in Patients with Completely Resected ROS1‑Positive Stage IB‑IIIA Non‑Small Cell Lung Cancer

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Taletrectinib
  • Sponsor:Nuvation Bio Inc.

Pulmonary hypertension

Not yet recruiting

Long‑Term Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

Major depression

Not yet recruiting

Long‑Term Safety, Tolerability and Efficacy of Azetukalner in Patients with Major Depressive Disorder

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Systemic scleroderma+1

Not yet recruiting

Study of CC-97540 (CD19‑Targeted NEX‑T CAR T) versus drug combination in adults with active systemic sclerosis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in L'hospitalet De Llobregat

What the registry says about research in the country

01 Infectious Disease Prevention

Innovative research focused on vaccine development targeting multiple infectious diseases, including studies on UTI prevention, yellow fever, and RSV protection in adults.

  • UTI Vaccine Safety & Efficacy
  • Yellow Fever Immunization
  • RSV Protection Studies

These trials aim to enhance vaccine effectiveness and improve public health outcomes through preventive measures.

02 Oncology Research

Comprehensive studies exploring new treatments for various types of advanced cancers, with particular focus on targeted therapies and novel drug combinations.

  • Colorectal Cancer Treatment
  • Gastric Cancer Therapies
  • Pancreatic Cancer Interventions

Advanced clinical research investigating innovative approaches to combat various forms of cancer.

03 Transplant Medicine

Groundbreaking research in kidney transplantation, focusing on preventing rejection and improving post-transplant outcomes.

  • Antibody-Mediated Rejection
  • Delayed Graft Function
  • Novel Immunosuppressive Approaches

Studies aimed at enhancing transplant success rates and patient recovery.

04 Autoimmune Conditions

Clinical investigations into treatments for various autoimmune disorders, including innovative therapies for inflammatory conditions.

  • Psoriatic Arthritis Treatment
  • Atopic Dermatitis Management
  • Myasthenia Gravis Therapy

Focused on developing targeted treatments to improve patient quality of life.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.